Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
https://www.fool.com/investing/2024/04/05/got-5000-these-3-high-yielding-dividend-stocks-are/?source=iedfolrf0000001
Apr 05, 2024 - All of these stocks pay generous dividends that income investors will appreciate.
0
The AI Race Gets Litigious
https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001
Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
0
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/04/25/gilead-sciences-gild-q1-2024-earnings-call-transcr/?source=iedfolrf0000001
Apr 25, 2024 - GILD earnings call for the period ending March 31, 2024.
0
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367
Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
0
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
0
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414
Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
0
Where Are Biotech ETFs Headed After Q4 Earnings?
https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390
Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
0
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
https://www.zacks.com/stock/news/2263449/gilead-gild-q1-loss-narrower-than-expected-sales-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2263449
Apr 26, 2024 - Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
0
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
https://www.zacks.com/stock/news/2200585/gilead-gild-compugen-collaborate-for-immunotherapy-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200585
Dec 20, 2023 - Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
0
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
https://www.zacks.com/stock/news/2201158/biotech-stock-roundup-cgen-up-on-gild-deal-mrna-gains-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2201158
Dec 21, 2023 - Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
0
Pages: 12
Page 1